Generics news from FierceBiotech
NewsSpectrum sells off generic drugs
Specturm Pharmaceuticals has sold its abbreviated NDAs for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Read more...
ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
> Jim Reddoch, a biotech analyst with Friedman, Billings & Ramsey, is raising some interesting questions about Genentech's second-generation Read more...
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
ALSO NOTED: US Oncology's CFO retires; Profits rise at Novartis, Merck, Lilly; and much more...
> US Oncology's CFO Rick McCook is resigning to explore opportunities in a retail or manufacturing business. Read more...
ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...
> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At Read more...
Can Big Pharma effectively develop new drugs?
When it comes to drug development, is bigger really better? That is the question Borje Eckholm, president and CEO of Investor AB--and one of AstraZeneca's biggest shareholders--poses in the London Read more...
Novartis discovery chief departs in management shakeup
Restructuring under the gun of new generics and after being slammed by regulatory defeats, Novartis is bidding adieu to James Shannon, its chief of global drug development. In his place Novartis has Read more...
ALSO NOTED: Harvard launches fund for biomedical tech; Neurogen outlines R&D plans; and much more...
> Harvard University's Office of Technology Development has launched the second round of its Technology Development Accelerator Fund, a new initiative designed to propel emerging technologies Read more...
The 2008 Election: What does it mean for drugmakers?
The winner of the 2008 election will be faced with making key decisions on a number of issues important to drug developers. Questions as to whether there will be more federal funding for stem cell Read more...
| Press ReleasesPRESS RELEASE: CRESTOR ANDA CRESTOR ANDA On 30th October 2007, AstraZeneca received a notice-letter from Cobalt Pharmaceuticals, Inc. (“Cobalt”) notifying AstraZeneca Pharmaceuticals LP, AstraZeneca AB, IPR Pharmaceuticals Read more... PRESS RELEASE: FDA Announces Initiative to Bolster Generic Drug Program FDA Announces Initiative to Bolster Generic Drug Program Effort will streamline generic drug approval process; provide more options for consumers, health professionals The U.S. Food and Drug Read more... PRESS RELEASE: US federal appeals court temporarily stops Teva from selling its generic version of fAMVIR US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir US Court of Appeals for the Federal Circuit issues order prohibiting Teva from Read more... PRESS RELEASE: Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets; Novartis’ Motion for Preliminary Injunction Denied JERUSALEM, Israel--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) Read more... |
Get more Generics coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight